Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Melanoma
Drug:
Proleukin (aldesleukin)
(
IL-2 stimulant
,
CD122 agonist
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
FDA
Published date:
07/30/2012
Excerpt:
Proleukin is indicated for the treatment of adults with metastatic melanoma.
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login